CMS VAD proposal an incremental positive for Thoratec, says Leerink

theflyonthewall.com

Leerink said the CMS ventricular assist device, or VAD, national coverage determination was largely in line with Street expectations and is an incremental positive for Thoratec (THOR) given the Bridge-to-Transplant vs. Destination Therapy destination remains intact. The firm said the proposal could be a perceived negative for HeartWare (HTWR) given some investors hoped for elimination of the designation.

Rates

View Comments (0)